ERNA · Ernexa Therapeutics Inc.
$2.24
+0.26 (+13.13%)
At close · Oct 20
Return incl. dividend (before tax)
Going-concern doubt
— cleared Aug 6, 2026
The latest filing states the doubt was alleviated.
“As of June 30, 2026, the Company had approximately $5.0 million in cash, which is less than that needed to effect its current operating plan and forecasted cash requirements for the next twelve months. However, management expects that its ability to access capital under its ATM will cover shortfalls in its cash resources over the next twelve months from the issuance date of these financial statements.”View the 10-Q filed Aug 6, 2026
Market Cap
$3.23M
Shares
1.63M
Volume · Oct 20
44.01K
Avg daily vol (3M)
60.05K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.98
Open$2.04
Day$1.84–2.07
52W close$1.98–47.00
Avg vol 30d71K
Short int20K · 1.2% float · 1.0d
Short vol16%
Last earningsAug 7, 2020
DataJan 2020–Oct 2026
Filing10-Q · Aug 6
Up next
filed Aug 6, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$582,000
Trailing 12 months
Net income (TTM)
−$12.26M
Trailing 12 months
Revenue growth YoY
+755.9%
Year over year
Operating margin
-2,693.1%
Trailing 12 months
P / E (TTM)
0.3
Trailing earnings · reciprocal yield 333.3%
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+471.5%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
1.2%
Latest settlement · 1.0 days to cover
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Bearish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 18.4 · elevated
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−77%
below
Price vs 50-day avg
−47%
below
RSI (14)
23
oversold
MACD trend
Negative
52-week position
0%
near low
Volume (OBV)
Bullish div.
accumulating
Momentum
relative strength
1-month return
−50%
trailing
6-month return
−58%
trailing
YTD return
−93%
this year
Relative strength
−66%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $4 › 200d $9 — 200d above 50d
Institutional flow
Distributing
-26% holders QoQ · +3 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
1.21% of float · ▲ +37.4% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
17 holders — mid 3-yr range
Squeeze score
43
elevated · 0–100
Fundamentals
Revenue growth
+756%
Y/Y
Gross margin
84%
expanding
EPS growth
+95%
Y/Y
Free cash flow
$-7.1M
Balance sheet
$1.3M
net debt
Quant / Vol
risk profile
Volatility
157%
annualized · 1-yr
Max drawdown
−96%
past year
ATR
16.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−77%
Bearish
Price vs 50-day avg
−47%
Bearish
RSI (14)
23
Neutral
MACD trend
Negative
Bearish
52-week position
0%
Bearish
Volume (OBV)
Bullish div.
Bullish
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $4 › 200d $9 — 200d above 50d
Institutional flow
Distributing
-26% holders QoQ · +3 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
1.21% of float · ▲ +37.4% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
17 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $2
Now $2 · 0%
Range high $47
vs 200-day avg -77%
vs 50-day avg -47%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ERNA
this stock
Ernexa Therapeutics Inc.
|
$3.23M | — | +755.9% | — | 1.2% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$130.07B | +10.7% | +46.2% | 29.9 | 1.8% |
|
MRNA
Moderna, Inc.
|
$90.58B | +669.4% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$80.51B | +1.3% | +20.8% | 19.4 | 2.1% |
|
CSLLY
Csl Ltd
|
$64.50B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ERNA | -10.4% | -50.0% | -58.3% | -38.1% | -93.4% |
| SPY | -1.5% | -0.9% | +7.7% | +0.5% | +12.4% |
| vs SPY | -8.9% | -49.1% | -66.0% | -38.6% | -105.8% |